Cargando…

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody

The effectiveness of SARS-CoV-2 vaccines and therapeutic antibodies have been limited by the continuous emergence of viral variants and by the restricted diffusion of antibodies from circulation into the sites of respiratory virus infection. Here, we report the identification of two highly conserved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Cheng, Zhan, Wuqiang, Yang, Zhenlin, Tu, Chao, Hu, Gaowei, Zhang, Xiang, Song, Wenping, Du, Shujuan, Zhu, Yuanfei, Huang, Keke, Kong, Yu, Zhang, Meng, Mao, Qiyu, Gu, Xiaodan, Zhang, Yi, Xie, Youhua, Deng, Qiang, Song, Yuanlin, Chen, Zhenguo, Lu, Lu, Jiang, Shibo, Wu, Yanling, Sun, Lei, Ying, Tianlei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907017/ https://www.ncbi.nlm.nih.gov/pubmed/35344711 http://dx.doi.org/10.1016/j.cell.2022.03.009

Ejemplares similares

A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants
por: Yang, Zhenlin, et al.
Publicado: (2021)

Inhalable antibodies for the treatment of COVID-19
por: Yang, Zhenlin, et al.
Publicado: (2022)

Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer
por: Zhan, Wuqiang, et al.
Publicado: (2022)

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
por: Tian, Xiaolong, et al.
Publicado: (2022)

Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
por: Zang, Jinkai, et al.
Publicado: (2021)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

Identification of Human Single-Domain Antibodies against SARS-CoV-2
por: Wu, Yanling, et al.
Publicado: (2020)

Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization
por: Yang, Jing, et al.
Publicado: (2023)

Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
por: Wang, Lili, et al.
Publicado: (2019)

A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
por: Wang, Yingdan, et al.
Publicado: (2022)

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody
por: Tian, Xiaolong, et al.
Publicado: (2020)

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
por: Wang, Yingdan, et al.
Publicado: (2022)

Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn
por: Gong, Rui, et al.
Publicado: (2012)

Retraction Note to: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

RETRACTED ARTICLE: SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion
por: Wang, Xinling, et al.
Publicado: (2020)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections
por: Huang, Keke, et al.
Publicado: (2022)

Single-Domain Antibodies As Therapeutics against Human Viral Diseases
por: Wu, Yanling, et al.
Publicado: (2017)

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
por: Ying, Tianlei, et al.
Publicado: (2015)

Evaluation of vaccine effectiveness against SARS‐CoV‐2 variants by serological epitope profiling
por: Li, Cheng, et al.
Publicado: (2023)

Fortuitous Somatic Mutations during Antibody Evolution Endow Broad Neutralization against SARS-CoV-2 Omicron Variants
por: Wu, Jianbo, et al.
Publicado: (2022)

Fortuitous somatic mutations during antibody evolution endow broad neutralization against SARS-CoV-2 Omicron variants
por: Wu, Jianbo, et al.
Publicado: (2023)

Bispecific Antibody Inhalation Therapy for Redirecting Stem Cells from the Lungs to Repair Heart Injury
por: Liu, Mengrui, et al.
Publicado: (2020)

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections
por: Wagh, Kshitij, et al.
Publicado: (2018)

A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo
por: Li, Fanlin, et al.
Publicado: (2023)

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual
por: Guerra, Denise, et al.
Publicado: (2023)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
por: Wang, Xinling, et al.
Publicado: (2021)

A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A
por: Xu, Tianshu, et al.
Publicado: (2017)

IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer
por: Wang, Lei, et al.
Publicado: (2022)

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD
por: Zhou, Yunjiao, et al.
Publicado: (2021)

Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit
por: Cai, Yanxing, et al.
Publicado: (2020)

Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS)
por: Lu, Lu, et al.
Publicado: (2015)

A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome
por: Jiang, Shibo, et al.
Publicado: (2020)

Defining a highly conserved cryptic epitope for antibody recognition of SARS-CoV-2 variants
por: Hao, Aihua, et al.
Publicado: (2023)

A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors
por: Wu, Yanling, et al.
Publicado: (2022)

Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2
por: Liu, Yinghui, et al.
Publicado: (2021)

The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2
por: Li, Cheng, et al.
Publicado: (2021)

An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants
por: Liu, Juan, et al.
Publicado: (2023)

Endovascular treatment with in-vitro fenestration and sac filling technique for ruptured thoracoabdominal aortic aneurysm with Behcet’s disease
por: Xia, Shibo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m5blp9a25oefp1egbmm7c08kth